Vantia Ltd
12
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
Role: lead
Efficacy and Safety of VA106483 in Elderly Males
Role: lead
VA106483 Dose Response Study in Elderly Males
Role: lead
A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval
Role: lead
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon
Role: lead
Efficacy Study of VA106483 in Males With Nocturia.
Role: lead
Dose Range Finding Study of Fedovapagon in Men With Nocturia
Role: lead
VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept
Role: lead
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
Role: lead
VA106483 Dose Response in Females
Role: lead
VA106483 and Alpha Blocker Interaction Study in Elderly Males
Role: lead
VA111913 TS: First in Human Study
Role: lead
All 12 trials loaded